scholarly journals EP-1184: Hypofractionated simultaneous integrated boost radiotherapy after breast-conserving surgery: 3 years follow-up

2015 ◽  
Vol 115 ◽  
pp. S642-S643
Author(s):  
I. Linares ◽  
I. Tovar ◽  
R. Del Moral ◽  
M. Zurita ◽  
R. Guerrero ◽  
...  
Keyword(s):  
Breast Conserving Surgery ◽  
Simultaneous Integrated Boost ◽  
Integrated Boost ◽  
Boost Radiotherapy

scholarly journals Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis

2021 ◽  
Vol 20 ◽  
pp. 153303382110647
Author(s):  
Jinling Dong ◽  
Ya Yang ◽  
Dan Han ◽  
Qian Zhao ◽  
Chengxin Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Skin Toxicity ◽  
Breast Conserving Surgery ◽  
Simultaneous Integrated Boost ◽  
Conventional Fractionation ◽  
Tumor Bed ◽  
Integrated Boost ◽  
Radiation Pneumonia ◽  
Boost Radiotherapy

Purpose: The objective of this retrospective study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost radiotherapy for early breast cancer patients undergoing breast-conserving surgery. Methods: A total of 185 women with early breast cancer undergoing breast-conserving surgery were retrospectively divided into hypofractionated simultaneous integrated boost group and conventional fractionation group. Hypofractionated simultaneous integrated boost included 104 patients and the dose of whole-breast radiation reached 42.56 Gy in 16 fractions and simultaneously tumor bed boost to 48 Gy in 16 fractions, which course of radiotherapy was 22 days. The 81 patients of the conventional fractionation group received whole breast radiation to 50 Gy in 25 fractions and followed by tumor bed boost to 10 Gy in 5 fractions, which course of radiotherapy was 40 days. Clinical information including patients’ characteristics, skin toxicity, myelosuppression, radiation pneumonia, and cosmetic effects was recorded to analyze the influence of age, chemotherapy, position, and breast volume on the results of radiotherapy. Results: Hypofractionated simultaneous integrated boost group had no case of recurrence after a median follow-up of 25.6 months (9-47 months)) as compared with 2 after a median follow-up of 33.4 months (25-45 months) in the conventional fractionation group. The 2 groups had similar results in skin toxicity, cosmetic outcomes, and radiation pneumonia. In terms of myelosuppression, grade 1, grade 2, and grade 3 of myelosuppression in the hypofractionated simultaneous integrated boost group accounted for 16.7%, 12.3%, and 3.5% as compared with 30.0%, 21.1%, and 12.3% of the conventional fractionation group, respectively ( P = .000). Conclusions: HF-SIB RT is a considerable option in patients after breast-conserving surgery with a lower degree of myelosuppression and shorter treatment time.

scholarly journals IMAT-IGRT Treatment with Simultaneous Integrated Boost as Dose Escalation for Patients with Cervical Cancer: A Single Institution, Prospective Pilot Study

2021 ◽  
Vol 27 ◽  
Author(s):  
Zoltán Lőcsei ◽  
Klára Sebestyén ◽  
Zsolt Sebestyén ◽  
Eszter Fehér ◽  
Dorottya Soltész ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Total Dose ◽  
Dose Escalation ◽  
Tumor Regression ◽  
Simultaneous Integrated Boost ◽  
Disease Stage ◽  
Mri Scan ◽  
Regression Rate ◽  
Integrated Boost

Purpose: The aim of this study was to introduce the simultaneous integrated boost (SIB) technique to assess the safety of replacement of the brachytherapy (BT) boost for ineligible patients with cervical cancer receiving radiochemotherapy (RCT).Methods: Fourteen patients were enrolled between 2015 and 2018. SIB was delivered using RapidArc technique at doses of 2.4 Gy per fraction during pelvic irradiation with 50.4/1.8 Gy in seven patients (to a total dose of 67.2 Gy) with limited volume disease. In 7 patients with a more advanced disease stage (>5 cm tumor, parametric invasion both sides), parametric boost therapy was added to the pelvic radiotherapy to a total dose of the macroscopic tumor of 79.2 Gy. All patients received simultaneous cisplatin-based chemotherapy for 5 cycles with a dosage of 40 mg/m2. We examined acute toxicity (CTCAE v4.1) and quality of life (EORTC QLQ30 and CX24). The tumor regression rate was evaluated with RECIST 1.1 after the first 3- to 4-months follow-up Magnetic Resonance Imaging (MRI) scan. We calculated the percentage of tumor regression rate and the local control during the follow-up period and evaluated the survival data.Results: Our patient data are presented at a median follow-up time of 24.5 months. During the treatment period, no grade 3 to 4 toxicity was observed. During the follow-up period, no late-onset toxicity was observed. The tumor regression rate at the first MRI scan was 95.31% on average. Disease free survival (DFS) during the median follow-up of 24 months was 98.6%.Conclusion: In patients with cervical cancer, the SIB technique is amenable as part of definitive RCT. Dose escalation with the SIB technique can be safely administered to cervical cancer patients during definitive RCT if BT is not feasible. However, further randomized clinical studies are needed to validate the method, so routine use of it cannot be recommended yet.

EP-1228: Adjuvant radiotherapy using simultaneous integrated boost technique for breast conserving surgery

2014 ◽  
Vol 111 ◽  
pp. S65
Author(s):  
R. Del Moral ◽  
I. Tovar ◽  
M. Zurita ◽  
R. Guerrero ◽  
M. Martínez ◽  
...  
Keyword(s):  
Adjuvant Radiotherapy ◽  
Breast Conserving Surgery ◽  
Simultaneous Integrated Boost ◽  
Integrated Boost

scholarly journals Moderately Hypofractionated Intensity Modulated Radiotherapy (IMRT) With a Simultaneous Integrated Boost for Locally Advanced Head and Cancer – Do Modern Techniques Held Their Promise?

2021 ◽  
Author(s):  
Jörn Wichmann ◽  
Martin Durisin ◽  
Robert Michael Hermann ◽  
Roland Merten ◽  
Hans Christiansen
Keyword(s):  
Locally Advanced ◽  
Intensity Modulated Radiotherapy ◽  
Simultaneous Integrated Boost ◽  
Advanced Head ◽  
Intensity Modulated ◽  
Regional Control ◽  
Integrated Boost ◽  
Long Term Follow Up

Abstract PurposeIntensity-modulated-radiotherapy (IMRT) is still a standard of care for radiotherapy in locally advanced head and neck cancer (LA-HNSCC). Simultaneous-integrated-boost (SIB) and moderately hypofractionation offer an opportunity of individual dose painting and reduction of overall treatment time. We present retrospective data on toxicity and local-regional-control of a patient cohort with LA-HNSCC treated with an IMRT-SIB-concept in comparison to normofractionated 3D-conformal radiotherapy (3D-RT) after a long-term follow-up.MethodsBetween 2012 and 2014, n=67 patients with HNSCC (stages III/IV without distant metastases) were treated with IMRT-SIB either definitive (single/total doses: 2.2/66Gy, 2.08/62.4Gy, 1.8/54Gy in 30 fractions) or in the postoperative setting (2.08/62.4Gy, 1.92/57.6Gy, 1.8/54Gy). These patients' clinical course was matched (for gender, primary, and treatment concept) as part of a matched-pair-analysis with patients treated before mid-2012 with normofractionated 3D-CRT (definitive: 2Gy/50Gy followed by a sequential boost up to 70Gy; postoperative: 2Gy/60-64Gy). Chemotherapy/immunotherapy was given concomitantly in both groups in the definitive situation (postoperative dependent on risk factors). Primary endpoints were acute and late toxicity; secondary endpoint was loco-regional-control (LRC).Results67 patients treated with IMRT-SIB (n = 20 definitive, n = 47 adjuvant) were matched with 67 patients treated with 3D-RT. There were minor imbalances between the groups concerning non-matching-variables like extracapsular extension (ECE) and chemotherapy in IMRT-SIB.Significantly less toxicity was found in favor of IMRT-SIB concerning dysphagia, radiation dermatitis, xerostomia, fibrosis, and lymphoedema. After a median follow-up of 63 months, median LRC was not reached (IMRT-SIB) vs. 69.5m (3D-RT) (p=0.63).ConclusionThis moderately hypofractionated IMRT-SIB-concept showed to be feasible with less toxicity compared to conventional 3D-RT in this long-term follow-up observation.

scholarly journals Reduced Time and Toxicity with SIB IMRT in Carcinoma Breast

2015 ◽  
Vol 3 (3) ◽  
pp. 561-565
Author(s):  
Rashi Agrawal ◽  
Sandeep Agrawal ◽  
Sudarsan De
Keyword(s):  
Treatment Duration ◽  
Treatment Time ◽  
Breast Conservation ◽  
Simultaneous Integrated Boost ◽  
Breast Conservation Surgery ◽  
Overall Treatment Time ◽  
Image Guided Radiotherapy ◽  
Carcinoma Breast ◽  
Integrated Boost

Introduction: To reduce treatment duration, we are treating our carcinoma breast patients with simultaneous integrated boost radiotherapy after breast conservation surgery. Here we are presenting our experience at median follow up of three years. Material and methods: Patients having at least 6 months of follow up after completion of radiotherapy were evaluated .All patients were treated with intensity modulated image guided radiotherapy technique. Dose prescribed to clinical target volume breast was 50 Gy in 25 fractions and CTV boost was 60 Gy in 25 fractions. Results: Median age of our patients was 49 years. Five patients (10.2%) had acute grade 2 skin toxicity and all other (89.7%) grade 1.Grade 2 toxicity was noted in patients with pendulous and bulky breast. Average treatment duration was 34 days (range 32-56 days). Median follow up is three years after completion of radiotherapy. Twenty six (53.06 %) patients had late grade zero and twenty three (46.9% ) grade 1 skin reactions.Conclusion: With simultaneous integrated boost in carcinoma breast patients, overall treatment time can be reduced without increasing early and late toxicities. Implementation is easy with decreased replanning workload. Henceforth SIB can be a feasible option for early breast cancer patients.Int J Appl Sci Biotechnol, Vol 3(3): 561-565

Sign in / Sign up

Export Citation Format

Share Document